BioCentury
ARTICLE | Clinical News

Dalbavancin: Phase III data

August 16, 2004 7:00 AM UTC

In a double-blind Phase III trial in 565 patients with uncomplicated SSSIs, dalbavancin was non-inferior to cefazolin followed by oral cephalexin. Specifically, 89.1% of evaluable dalbavancin patients...